A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

Status:	Completed
Conditions:	Hepatitis, Hepatitis
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	5/10/2018
Start Date:	March 15, 2016
End Date:	May 26, 2017

A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection

The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with
Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients
with liver cirrhosis.

For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation,
please visit www.BMSStudyConnect.com

Inclusion Criteria:

- Genotype 3 HCV

- HCV RNA ≥10000 IU (International Unit)/mL

- Compensated Liver Cirrhosis

- BMI 18-40 kg/m2

- Previously treated for HCV or never treated for HCV

Exclusion Criteria:

- Infection with HCV other than Genotype 3. Mixed infection of any genotype

- Evidence of decompensated liver disease

- Previous exposure to NS5A inhibitors

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

Inova Fairfax Hospital

3300 Gallows Road
Falls Church, Virginia 22042

(703) 776-4001